Immunorizon

Company Overview

Snapshot

Founded in December 2017, Immunorizon operates with 1–10 employees. The company has secured funding across 3 rounds from 2 investors, with M Ventures participating in multiple rounds. A significant milestone for the company was its acquisition by Purple Biotech in February 2023.

Business overview

Immunorizon is a Health Tech & Life Sciences company focused on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company's core technology involves extending its pipeline and utilizing tri-specific constructs with additional tumor-associated antigens and diverse engagers for both T-cells and NK-cells. Operating within the Pharmaceuticals sector, Immunorizon serves the oncology and immunology markets with its biotechnology solutions.

Strategic signal

The acquisition of Immunorizon by Purple Biotech in February 2023 signals a strategic validation of its T- and NK-cell engager technology. This event indicates that Immunorizon's approach to cancer therapy, utilizing tri-specific constructs, has reached a level of maturity and potential that attracted a larger player in the biotechnology space, suggesting a positive outlook for the integration and further development of its pipeline.

Company Intelligence Q&A

What is Immunorizon's primary focus in cancer therapy?

Immunorizon specializes in developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with additional tumor-associated antigens.

When was Immunorizon founded?

Immunorizon was founded in December 2017.

Which company acquired Immunorizon?

Immunorizon was acquired by Purple Biotech in February 2023.

Which investor has participated in Immunorizon's funding rounds?

M Ventures has participated in Immunorizon's funding rounds, including in December 2017, April 2019, and February 2020.

What is the current employee count for Immunorizon?

Immunorizon currently has 1–10 employees.